Zydus Cadila has received the tentative approval from the USFDA to market Fingolimod Capsules, 0.5 mg. The drug is an immunomodulating drug, mostly used for treating multiple sclerosis  and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ, in Ahmedabad.

The sales of Fingolimod Capsules is estimated at USD 2.1 billionn. Source: IMS Health, IMS National Sales Perspective Audit, MAT May 2017, extracted July 2017.
 
The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.  

Shares of the company gained Rs 13.9, or 2.68%, to settle at Rs 532.50. The total volume of shares traded was 152,487 at the BSE (Friday).